We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $29.69, moving +1.24% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.31%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 1.38%.
Prior to today's trading, shares of the company had lost 1.58% lagged the Medical sector's gain of 2.58% and the S&P 500's gain of 0.87%.
Investors will be eagerly watching for the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 9, 2026. It is anticipated that the company will report an EPS of $0.07, marking a 16.67% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $893.37 million, showing a 49.15% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$0.79 per share and a revenue of $3.22 billion, demonstrating changes of -249.06% and +37.03%, respectively, from the preceding year.
Any recent changes to analyst estimates for Hims & Hers Health, Inc. should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Hims & Hers Health, Inc. is currently a Zacks Rank #3 (Hold).
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $29.69, moving +1.24% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.31%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 1.38%.
Prior to today's trading, shares of the company had lost 1.58% lagged the Medical sector's gain of 2.58% and the S&P 500's gain of 0.87%.
Investors will be eagerly watching for the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 9, 2026. It is anticipated that the company will report an EPS of $0.07, marking a 16.67% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $893.37 million, showing a 49.15% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$0.79 per share and a revenue of $3.22 billion, demonstrating changes of -249.06% and +37.03%, respectively, from the preceding year.
Any recent changes to analyst estimates for Hims & Hers Health, Inc. should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Hims & Hers Health, Inc. is currently a Zacks Rank #3 (Hold).
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.